Solid Lipid Nanoparticles (sLNPs) are submicron particles made of stable, biocompatible lipids used as drug delivery systems. Developed in the 1990s by combining polymeric nanoparticles, liposomes and fat emulsions, these formulations offer advantages such as enhanced stability, biocompatibility, reduced toxicity, increased absorption and scalability. These benefits improve the bioavailability of poorly water-soluble drugs. This article covers the structure, preparation, applications, limitations and prospects of SLNs.

What is the composition of SLNs?

Solid lipid nanoparticles comprise a solid lipid core and stabilizing surfactants. The solid lipid core consists of biocompatible lipids, such as di- or triglycerides, steroids and fatty acids. It forms a lipid matrix that encapsulates the drug molecule, protects it from degradation and facilitates controlled, sustained release. Surfactants (emulsifiers), such as lecithin, PEG-35 castor oil and polyoxyethylene (20) oleyl ether, stabilize the nanoparticles while preventing their agglomeration.²

The lipid matrix type significantly influences the drug encapsulation efficiency of SLNs. There are three types of lipid matrix forms, depending on how the drug is dispersed throughout the solid lipid nanoparticle.¹

The solid lipid core distinguishes SLNs from liquid lipid nanoparticles, often presenting stability and drug leakage issues. Liquid delivery systems include lipospheres, lipid-drug conjugates and lipid emulsions.³

How do solid lipid nanoparticles compare to liposomes?

Preparation and Formulation Techniques

The formulation and methodology used to prepare SLNs greatly influence their size, encapsulation efficiency, stability and drug release behavior. The type of biocompatible lipid and the temperature conditions are also crucial. The goal during SLN preparation is to produce uniform particles with diameters of 50-500 nm.¹

Common preparation methods include:

1. High-pressure homogenization (cold/hot)
2. Ultrasonication
3. Solvent emulsification-evaporation
4. Microemulsion-based techniques
5. SLN preparation by using supercritical fluid

Mechanism of Drug Delivery

During the preparation phase, the drug is incorporated into solid lipid nanoparticles in different structural configurations:

• Uniform distribution throughout the lipid matrix
• Formation of a crystallized drug shell surrounding the lipid core
• Development of a drug-enriched core with a lipid outer layer

Drug release from solid lipid nanoparticles depends on several factors, including the production temperature, drug distribution, pH and surfactant concentration. Controlled and sustained drug release is essential in drug delivery, as it extends the therapeutic window and reduces the need for re-administration.²

SLNs can be administered via parenteral, dermal oral and pulmonary routes. Their small particle size is highly advantageous for parenteral and targeted drug delivery. SLNs can be delivered via intravenous, subcutaneous and intramuscular injection, allowing precise targeting of organs and tumors.¹

Key advantages of SLNs over liposomes and polymeric nanoparticles include:

• Ability to evade reticuloendothelial system (RES) clearance in the spleen and liver⁴
• Enhanced permeation and retention when modified with targeting ligands (e.g., PEGylation)⁴

Additional advantages include²:

• Improved stability
• Increased bioavailability
• Ease of large-scale production
• Reduced drug leakage

Characterization of SLNs as a Drug Delivery System

Manufacturers should comprehensively characterize solid lipid nanoparticles to ensure their quality, safety and stability. Several analytical techniques are employed to evaluate various structural and functional parameters, including:¹

1. Entrapment efficiency is described as the ratio of the amount of the encapsulated drug to the total amount of drug used during SLN preparation.
2. Particle size distribution is one of the most crucial parameters affecting bioavailability and cellular uptake. It can be measured using dynamic light scattering (DLS), transmission electron microscopy and atomic force microscopy.
3. Polydispersity Index (PDI) indicates the uniformity of particle size, which can be measured via DLS.
4. Zeta potential is used to measure the surface electrical potential relative to the medium, which indicates colloidal stability. A higher zeta potential is associated with better colloidal stability.
5. Chemical stability is measured by differential scanning calorimetry, which reveals the SLN-drug system's thermal stability, potential for crystallization and degradation.
6. The drug release profile measures the rate of drug release into the surrounding medium, often represented as mg of drug/hr. It is a vital measure of the therapeutic window and bioavailability.

Advantages of Using Solid Lipid Nanoparticles

Solid lipid nanoparticles are a potential option for drug delivery due to several advantages they offer:¹

1. Biocompatibility and biodegradability: The lipid core comprises biologically relevant lipids well-tolerated by the body and broken down into non-toxic byproducts, minimizing the risk of adverse effects
2. Improved stability and solubility of APIs: SLNs are often used to encapsulate and deliver poorly water-soluble drugs, improving their solubility and protecting them from degradation
3. Reduced systemic toxicity and side effects: The controlled drug release profile ensures the drug's delivery is concentrated at the desired site, minimizing exposure to healthy tissues
4. Scalable production and low-cost lipid materials: Many solid lipid nanoparticle preparation techniques, such as high-pressure homogenization, are scalable and cost-effective, making them suitable for industrial and clinical manufacturing

Challenges and Limitations

Despite their several advantages and clinical potential, solid lipid nanoparticles pose some challenges.²

1. Stability Issues due to polymorphic transitions and lipid crystallization may lead to unintended drug expulsion
2. Drug degradation due to high-pressure techniques applied during formulation
3. Controlling particle size and aggregation
4. Unintended gelation
5. Compromised encapsulation efficiency due to suboptimal pH, temperature and impurities
6. The potential toxicity of lipids and surfactants used in preparation requires additional quality control steps

Applications of Solid Lipid Nanoparticles for Drug Delivery

Solid lipid nanoparticles (SLNs) are popular in drug delivery because of their structure and functions. Their protective shell supports various methods like oral, parenteral, ocular, pulmonary and topical. The lipid core can be tailored to enhance solubility and permeability of hydrophilic and hydrophobic drugs.² They can encapsulate and stabilize labile biopharmaceuticals, such as therapeutic proteins, peptides and mRNA, which can be used in developing advanced vaccines and biologics.⁵,⁶

SLNs are particularly promising for targeted delivery of anticancer drugs:

• Help address key limitations of conventional chemotherapy:

  • High systemic toxicity
  • Severe off-target side effects

• Provide controlled drug release, which:

  • Minimizes exposure to healthy cells
  • Promotes localized delivery at tumor sites

• Their nanoscale size enables:

  • Enhanced permeability and retention (EPR) in tumor vasculature
  • Improved infiltration of difficult-to-target solid tumors

• Surface engineering strategies can further enhance performance:

  • Improved bioavailability
  • Prolonged drug release

• SLN formulations have demonstrated improved efficacy and reduced side effects in multiple cancers, including breast, colorectal, lung, brain and prostate cancers.⁷

Besides cancer, SLNs are also investigated as gene vector carriers for delivering DNA, small-interfering RNA (siRNA) and messenger RNA (mRNA). Cationic lipids in SLNs can form lipid-nucleic acid complexes that enhance cellular uptake and promote gene expression, making them valuable in gene therapy and nucleic acid-based vaccine production.⁵^,⁸

SLNs are also studied and patented for various other conditions, ranging from tuberculosis to diabetes and hypertension.⁹⁻¹¹

References

1. Sangeetha S, Narayanasamy D. The Science of Solid Lipid Nanoparticles: From Fundamentals to Applications. Cureus 2024;16(9).
2. Akanda M, Mithu MSH, Douroumis D. Solid lipid nanoparticles: An effective lipid-based technology for cancer treatment. J Drug Deliv Sci Technol 2023;86:104709.
3. Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review. Pharmaceutics 2023;15(6):1593.
4. Amiri M, Jafari S, Kurd M, Mohamadpour H, Khayati M, Ghobadinezhad F, et al. Engineered solid lipid nanoparticles and nanostructured lipid carriers as new generations of blood–brain barrier transmitters. ACS Chem Neurosci 2021;12(24):4475-4490.
5. Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A recent update: solid lipid nanoparticles for effective drug delivery. Adv Pharm Bull 2021;12(1):17.
6. Zielińska A, Eder P, Karczewski J, Szalata M, Hryhorowicz S, Wielgus K, et al. Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. Front Immunol 2023;14:1147991.
7. Sivadasan D, Ramakrishnan K, Mahendran J, Ranganathan H, Karuppaiah A, Rahman H. Solid lipid nanoparticles: applications and prospects in cancer treatment. Int Journal Mol Sci 2023;24(7):6199.
8. Assefi M, Ataeinaeini M, Nazari A, Gholipour A, Vertiz-Osores JJ, Calla-Vásquez KM, et al. A state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system. J Drug Deliv Sci Technol 2023;86:104623.
9. Ma C, Wu M, Ye W, Huang Z, Ma X, Wang W, et al. Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties. Drug Deliv Transl Res 2021;11:1218-1235.
10. Sharma JB, Bhatt S, Saini V, Kumar M. Pharmacokinetics and pharmacodynamics of curcumin-loaded solid lipid nanoparticles in managing streptozotocin-induced diabetes mellitus: application of central composite design. Assay Drug Dev Technol 2021;19(4):262-279.
11. Dugad T, Kanugo A. Design optimization and evaluation of solid lipid nanoparticles of azelnidipine for the treatment of hypertension. Recent Pat Nanotechnol 2024;18(1):22-32.
12. Young H, He Y, Joo B, Ferguson S, Demko A, Butterfield SK, et al. Toward the scalable, rapid, reproducible, and cost-effective synthesis of personalized nanomedicines at the point of care. Nano Lett 2024;24(3):920-928.
13. Widyati R, Ashari A. A review of using data mining and machine learning for predicting drug loading modeling in solid lipid nanoparticles containing curcumin. Journal of Physics: Conference Series: IOP Publishing; 2021:042015.
14. Bhardwaj N, Kumar A, Kaur P, Arora S, Bedi N, Bhatia A. Erucin-loaded chitosan coated solid lipid hybrid nanoparticles: An efficient drug delivery system for enhancing solubility and sustained release. Int J Biol Macromol 2025;308:142350.
15. Pi C, Zhao W, Zeng M, Yuan J, Shen H, Li K, et al. Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo. Drug Deliv 2022;29(1):1878-1891.
16. Elkateb H, Cauldbeck H, Niezabitowska E, Hogarth C, Arnold K, Rannard S, et al. High drug loading solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsions for the dual drug delivery of the HIV drugs darunavir and ritonavir. JCIS Open 2023;11:100087.
17. López KL, Ravasio A, González-Aramundiz JV, Zacconi FC. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) prepared by microwave and ultrasound-assisted synthesis: promising green strategies for the nanoworld. Pharmaceutics 2023;15(5):1333.
18. Stahl MA, Lüdtke FL, Grimaldi R, Gigante ML, Ribeiro APB. Characterization and stability of α-tocopherol loaded solid lipid nanoparticles formulated with different fully hydrogenated vegetable oils. Food Chem 2024;439:138149.